Stabilization of fibrin clots by activated prothrombin complex concentrate and tranexamic acid in FVIII inhibitor plasma

Haemophilia

Volumn 17, Issue 5, 2011, Pages

  Dai, L ^a   Bevan, D ^a   Rangarajan, S ^a   Sorensen B ^a,b   Mitchell, M ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Combination of pd APCC and TXA; Fibrin clot stability

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8 INHIBITOR; TRANEXAMIC ACID;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD CLOTTING TIME; CLINICAL ARTICLE; EUGLOBULIN LYSIS TEST; FIBRIN CLOT; FIBRINOLYSIS; HEMOPHILIA A; HUMAN; MONOTHERAPY; PRIORITY JOURNAL; THROMBIN TIME; THROMBOSIS;

ADOLESCENT; ADULT; AGED; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; BLOOD COAGULATION TESTS; FIBRINOLYSIS; HEMOPHILIA A; HUMANS; MALE; MIDDLE AGED; THROMBIN; THROMBOSIS; TRANEXAMIC ACID;

EID: 80052022370     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2011.02491.x     Document Type: Article

References (27)

1. AI Dieri R, Peyvandi F, Santagostino E et al. The thrombogram in rare inherited coagulation disorders: its relation to clinical bleeding. Thromb Haemost 2002; 88: 576-82.
2. Mosnier LO, Lisman T, van den Berg HM, Nieuwenhuis HK, Meijers JC, Bouma BN. The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration. Thromb Haemost 2001; 86: 1035-9.
3. Oldenburg J, Brackmann HH, Schwaab R. Risk factors for inhibitor development in hemophilia A. Haematologica 2000; 85(10 Suppl.): 7-13.
4. Mehta R, Parameswaran R, Shapiro AD. An overview of the history, clinical practice concerns, comparative studies and strategies to optimize therapy of bypassing agents. Haemophilia 2006; 12(Suppl.6): 54-61.
5. Astermark J, Donfield SM, DiMichele DM et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007; 109: 546-51.
6. Kjalke M, Monroe DM, Hoffman M et al. The effects of activated factor VII in a cell-based model for tissue factor-initiated coagulation. Blood Coagul Fibrinolysis 1998; 9(Suppl.1): S21-5.
7. He S, Blomback M, Ekman JG, Hedner U. The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIII/FIX. J Thromb Haemost 2003; 1: 1215-9.
8. Lisman T, Mosnier LO, Lambert T et al. Inhibition of fibrinolyisis by recombinant factor VIIa in plasma from patients with severe hemophilia A. Blood 2002; 99: 175-9.
9. Varadi K, Negrier C, Berntorp E et al. Monitoring the bioavailability of FEIBA with a thrombin generation assay. J Thromb Haemost 2003; 1: 2374-80.
10. Levi M, Cromheecke ME, de Jonge E et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinical relevant endpoints. Lancet 1999; 354: 1940-7.
11. Johansson T, Pettersson L, Lisander B. Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients. Acta Orthop 2005; 76: 314-9.
12. Boylan JF, Klinck JR, Sandler AN et al. Tranexamic acid reduces blood loss, transfusion requirements, and coagulation factor use in primary orthotopic live transplantation. Anesthesiology 1996; 85: 1043-8.
13. Royston D. Blood-sparing drugs: aprotinin, tranexamic acid, and epsilon-aminocaproic acid. Int Anesthesiol Clin 1995; 33: 155-79.
14. Hiippala S, Strid L, Wennerstrand M et al. Tranexamic acid (Cyklokapron) reduces perioperative blood loss associated with total knee arthroplasty. Br J Anaesth 1995; 74: 534-7.
15. Veien M, Sorensen JV, Madsen F, Juelsgaard P. Tranexamic acid given intraoperatively reduces blood loss after total knee replacement: a randomized, controlled study. Acta Anaesthesiol Scand 2002; 46: 1206-11.
16. Sindet-Pederson S, Ingerslev J, Ramstrom G, Blomback M. Management of oral bleeding in haemophilic patients. Lancet 1988; 2: 566.
17. Baxter. Product Summary of pd-aPCC. Available at Accessed January 2, 2011.
18. Hvas AM, Sorensen HT, Norengaard L, Christiansen K, Ingerslev J, Sorensen B. Tranexamic acid combined with recombinant factor VIII increases clot resistance to accelerated fibrinolysis in severe hemophilia A. J Thromb Haemost 2007; 5: 2408-14.
19. Fiechtner BK, Nuttall GA, Johnson ME et al. Plasma tranexamic acid concentrations during cardiopulmonary bypass. Anesth Analg 2001; 92: 1131-6.
20. Dai L, Mitchell M, Savidge G, Alhaq A. The profibrinolytic effect of plasma thrombomodulin in factor XI deficiency and its implications in hemostasis. J Thromb Haemost 2004; 2: 2000-4.
21. Wolberg AS, Allen GA, Monroe DM, Hedner U, Roberts HR, Hoffman M. High dose factor VIIa improves clot structure and stability in a model of haemophilia B. Br J Haematol 2005; 131: 645-55.
22. Brummel-Ziedins KE, Branda RF, Butenas S, Mann KG. Discordant fibrin formation in hemophilia. J Thromb Haemost 2009; 7: 825-32.
23. Sorensen B, Persson E, Ingerslev J. Factor VIIa analogue (V158D/E286V/M298Q-FVIIa) normalises cot formation in whole blood from patients with severe haemophilia A. Br J Haematol 2007; 137: 158-65.
24. Turecek PL, Varadi K, Gritsch H et al. Factor Xa and prothrombin: mechanism of action of FEIBA. Vox Sang 1999; 77(Suppl.1): 72-9.
25. Schneiderman J, Rubin E, Nugent D, Young G. Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience. Haemophilia 2007; 13: 244-8.
26. Martinowitz U, Livnat T, Zivelin A, kenet G. Concomitant infusion of low doses of rFVIIa and FEIBA in haemophilia patients with inhibitors. Haemophilia 2009; 15: 904-10.
27. Teitel J, Berntorp E, Collins P et al. A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors. Haemophilia 2007; 13: 256-63.